--- title: "RSI Alert: Inspire Medical Systems (INSP) Now Oversold" type: "News" locale: "en" url: "https://longbridge.com/en/news/279489659.md" description: "Inspire Medical Systems (INSP) shares have entered oversold territory with a Relative Strength Index (RSI) of 29.2, indicating potential buying opportunities as heavy selling may be exhausting. The stock traded as low as $54.82, with a current price of $55.15, compared to a 52-week low of $53.11 and a high of $172.95. The S&P 500 ETF (SPY) has an RSI of 41.5, suggesting a contrasting market sentiment. Investors may consider this an opportune moment to buy as per Warren Buffett's advice on market behavior." datetime: "2026-03-17T20:50:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279489659.md) - [en](https://longbridge.com/en/news/279489659.md) - [zh-HK](https://longbridge.com/zh-HK/news/279489659.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/279489659.md) | [繁體中文](https://longbridge.com/zh-HK/news/279489659.md) # RSI Alert: Inspire Medical Systems (INSP) Now Oversold Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Inspire Medical Systems Inc (Symbol: INSP) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $54.82 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 41.5. A bullish investor could look at INSP's 29.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of INSP shares: Looking at the chart above, INSP's low point in its 52 week range is $53.11 per share, with $172.95 as the 52 week high point — that compares with a last trade of $55.15. * * * Never miss the next high-yield opportunity: **Preferred Stock Alerts** sends timely, actionable picks on income-producing preferred stocks and baby bonds, straight to your inbox. Find out what 9 other oversold stocks you need to know about » ##### Also see: • ETF Fund Flows • SPHS shares outstanding history • Earnings Surprises The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md) - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Inspire Medical Systems, Inc. (INSP.US)](https://longbridge.com/en/quote/INSP.US.md) - [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD](https://longbridge.com/en/news/281179756.md) - [MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation | VATE Stock News](https://longbridge.com/en/news/281183004.md) - [Perimeter Posts Record 2025 Revenue and Wins FDA Approval for AI Breast Imaging Device](https://longbridge.com/en/news/281274047.md) - [Canada's Perimeter Medical Imaging prelim Q4 revenue jumps 143%](https://longbridge.com/en/news/281240360.md) - [Cleo Diagnostics Hits Key U.S. Trial Milestone for Ovarian Cancer Test](https://longbridge.com/en/news/281095740.md)